Skip to content

Revolution Medicines

US · RVMD #499 by market cap Listed 2020
161.20 +1.77 +1.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
  • Total institutional ownership fell 1.3 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
99.79% -1.31pp
Institutions
904 -3
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund55.85%
Hedge Fund29.25%
VC/PE Fund7.30%
Public Company2.50%
Private Company2.20%
Individual/Insider2.14%
Sovereign Wealth Fund1.14%
Government Pension Fund1.09%
Family Office/Trust0.26%

Top holders as of 2026-09-30

FMR 7.00% · 15.13M sh
BlackRock 6.41% · 13.86M sh
Farallon Capital Management, L.L.C. 6.20% · 13.42M sh
Baker Bros. Advisors LP 4.92% · 10.64M sh
Darwin Global Management Limited 4.91% · 10.63M sh
Vanguard Capital Management, LLC 4.84% · 10.47M sh
Vanguard Portfolio Management, LLC 3.77% · 8.16M sh
Nextech Invest Ltd. 3.51% · 7.60M sh
Janus Henderson Group plc 3.50% · 7.57M sh
UBS Asset Management 2.90% · 6.28M sh
Paradigm Biocapital Advisors LP 2.97% · 6.36M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 12 buys · 38 sells

NameRoleStake
Alexis Borisy Lead Independent Director 1.08%
Mark Goldsmith Chief Executive Officer 0.36%
Thilo Schroeder Independent Director 0.35%
Stephen Kelsey Senior Advisor 0.10%
Margaret Horn Chief Operating Officer 0.04%
Sandra Horning Independent Director 0.04%
Jack Anders Chief Financial Officer 0.03%
Xiaolin Wang Executive Vice President of Integrated Portfolio Strategy & Management 0.03%
Alan Bart Sandler Chief Development Officer 0.02%
Elizabeth Anderson Independent Director 0.02%
Wei Lin Chief Medical Officer 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-10 Alexis Borisy Lead Independent Director Other Disposition -10,625 --
2026-11-10 Jack Anders Chief Financial Officer Derivative Exercise and Sale -35,750 $18.56–192.84
2026-11-08 Anthony Mancini Chief Global Commercialization Officer Derivative Exercise and Sale -811 $33.62–200.00
2026-10-25 Anthony Mancini Chief Global Commercialization Officer Derivative Exercise and Sale -2,310 $33.62–186.99
2026-09-28 Alan Bart Sandler Chief Development Officer Automatic Disposition -309 $203.91–204.72
2026-09-28 Alan Bart Sandler Chief Development Officer Derivative Exercise and Sale -6,000 $58.84–203.91
2026-09-24 Anthony Mancini Chief Global Commercialization Officer Derivative Exercise and Sale -3,121 $33.62–200.54
2026-09-24 Jeffrey Cislini Senior Vice President Automatic Disposition -765 $207.32
2026-09-23 Anthony Mancini Chief Global Commercialization Officer Automatic Disposition -587 $200.00
2026-09-21 Elizabeth Anderson Independent Director Automatic Disposition -5,073 $192.54–195.15
2026-09-21 Elizabeth Anderson Independent Director Derivative Exercise and Sale -5,070 $1.12–192.54
2026-09-17 Anthony Mancini Chief Global Commercialization Officer Automatic Disposition -1,764 $196.94
2026-09-15 Mark Goldsmith Chief Executive Officer Open Market Disposition -13,988 $195.01–199.30
2026-09-15 Margaret Horn Chief Operating Officer Automatic Disposition -4,967 $195.01–199.30
2026-09-15 Stephen Kelsey Senior Advisor Open Market Disposition -5,569 $195.01–199.30
2026-09-15 Alan Bart Sandler Chief Development Officer Automatic Disposition -341 $194.96–199.30
2026-09-15 Anthony Mancini Chief Global Commercialization Officer Open Market Disposition -1,774 $195.05–199.30
2026-09-15 Jack Anders Chief Financial Officer Open Market Disposition -4,053 $195.00–199.30
2026-09-15 Jeffrey Cislini Senior Vice President Open Market Disposition -3,366 $195.01–199.30
2026-09-14 Mark Goldsmith Chief Executive Officer Intent to Sell (Form 144) -13,603 $203.77

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.

Revolution Medicines discussion 0 comments

Add a comment